The study, funded by Aimmune Therapeutics, included 551 participants, all of whom were allergic to peanuts. Participants ranged in age from 4 to 55 years, although most of them were children aged 4 to 17 years. The researchers gave a quarter of the placebo participants, while three quarters received oral doses of a small amount of peanut protein powder, starting at half a milligram per day; the amount increased gradually until a maintenance dose of 300 milligrams was reached, which is equivalent to one peanut per day.
Source link
